GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alexion Pharmaceuticals, Inc. (ALXN) [hlAlert]

Rating:
Overweight
ALXN
down 9.21 %

Alexion Pharmaceuticals, Inc. (ALXN) rated Overweight by JP Morgan

Posted on: Monday,  Jul 27, 2015  10:25 AM ET by JP Morgan

JP Morgan rated Overweight Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 07/27/2015, when the stock price was $198.07. Since
then, Alexion Pharmaceuticals, Inc. has lost 9.21% as of 12/11/2015's recent price of $179.82.
If you would have followed this JP Morgan's recommendation on ALXN, you would have lost 9.21% of your investment in 137 days.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/27/2015 10:25 AM Buy
None
198.07
as of 8/27/2015
1 Week down  -5.16 %
1 Month down  -9.21 %
3 Months down  -9.21 %
1 YTD down  -9.21 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy